Natalie T. Mills

Jan 7, 2025 | cambridge.org | Natalie T. Mills |Stevan Nikolin |Nick Glozier |David Barton

Hostname: page-component-599cfd5f84-9hh9z Total loading time: 0 Render date: 2025-01-07T08:42:55.857Z Has data issue: false hasContentIssue false Published online by Cambridge University Press: 07 January 2025 Natalie T Mills [Opens in a new window] , Stevan Nikolin [Opens in a new window] , Nick Glozier [Opens in a new window] , Bernhard T Baune [Opens in a new window] , ...Show all authors Show author details Keywords Ketaminedepressionanxietyclinical trialmental health Type Original...

Oct 14, 2024 | dx.doi.org | Nick Glozier |David Barton |Bernhard T Baune |Natalie T. Mills

To save this article to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle. Note you can select to save to either the @free.kindle.com or @kindle.com variations.

Aug 26, 2024 | medrxiv.org | Natalie T. Mills |Thuc Duy Le |Elina Hyppönen |Lamessa Dube Amente

The authors have declared no competing interest. https://github.com/lamessad/MRLOVALamessa Amente acknowledges funding from the Australian Government Research Training Program (RTP) scholarship. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Oct 26, 2023 | psiquiatria.com | Emma Sampson |Natalie T. Mills

Objetivo El trastorno depresivo mayor (TDM) sigue siendo difícil de tratar, y muchos pacientes se resisten a los tratamientos existentes o experimentan recaídas. La disfunción cognitiva se asocia con resultados clínicos más graves. La vortioxetina ha demostrado eficacia para remediar el deterioro cognitivo asociado a la depresión.

Oct 4, 2023 | psychiatrist.com | Emma Sampson |Natalie T. Mills |Hikaru Hori |Kathrin Schwarte

ABSTRACTObjective: Major depressive disorder (MDD) remains difficult to treat, with many patients resistant to existing treatments or experiencing relapse. Cognitive dysfunction is associated with more severe clinical outcomes. Vortioxetine has shown efficacy in remediating depression-associated cognitive impairment. Anti-inflammatory augmentation of antidepressants is a new strategy in treating depression and has not previously been assessed for effects on cognition in depression.